Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD

Table 1 Patient and treatment characteristics

#	Age (years)	Gender	Diagnose	Disease status	Donor source	Conditioning regimen	Stem cell source	GVHD Prophylaxis	Onset of aGVHD after HSCT
1	44	Male	AML	CR	MUD(O → AB)	Bu/Cy	PB	CsA + MMF + MTX + ATG	22
2	59	Male	AML	Relapse	HRD(A → A)	CBA	BM + PB	CsA + MMF + MTX + ATG	19
3	34	Male	AML	CR	HRD(O → B)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	19
4	29	Female	AML	Refractory	HRD(B → B)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	10
5	40	Male	AML	Relapse	HRD(B → A)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	30
6	18	Male	SAA	NR	HRD(A → B)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	20
7	29	Male	AML	CR	HRD(B → B)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	30
8	18	Female	ALL	CR	HRD(B → B)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	25
9	47	Male	AML	CR	HRD(O → A)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	97
10	21	Female	ALL	CR	HRD(O → B)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	42
11	28	Female	AML	CR	HRD(A → A)	Bu/Cy	BM + PB	FK506 + MMF + MTX + ATG	22
12	47	Male	MDS	PD	HRD(B → O)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	17
13	16	Male	SAA	NR	HRD(AB → AB)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	18
14	23	Female	AML	CR	HRD(A → A)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	22
15	38	Male	AML	CR	HRD(B → B)	Bu/Cy	PB	CsA + MMF + MTX + ATG	55
16	15	Female	MDS	NR	HRD(B → B)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	24
17	25	Male	AML	Relapse	HRD(O → B)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	51
18	45	Male	HAL	CR	HRD(O → O)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	100
19	16	Male	ALL	Refractory	HRD(A → A)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	28
20	26	Male	MDS	PD	HRD(AB → AB)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	23
21	54	Male	AML	CR	HRD(O → O)	Bu/Cy	BM + PB	CsA + MMF + MTX + ATG	22

#	Additional organ involvement to intestine manifestations	aGVHD grade	Response to combined treatment	Virus reactivation after combined treatment	Infection after combined treatment	Severe cytopenia	Last fellow-up (days after response)	Status	GVHD relapse (severity, days after response)
1	None	III	NR	CMV	–	3	111	Dead	–
2	Skin and liver	IV	NR	–	–	4	40	Dead	–
3	Skin	IV	PR	–	–	4	127	Dead	Intestine (1, + 47d)
4	Skin and liver	IV	NR	–	–	4	22	Dead	–
5	Skin and liver	III	PR	CMV	–	–	73	Dead	–
6	None	III	CR	CMV enteritis	–	–	677	Alive	–
7	Skin and liver	III	PR	–	–	4	661	Alive	Skin, intestine (2, + 88d)
8	Skin	III	PR	CMV enteritis, EBV	–	–	685	Alive	–
9	None	III	CR	Urinary polyomavirus	Intestinal infection	3	707	Alive	Intestine (2, + 226d)
10	Skin and liver	IV	NR	–	Intestinal infection Fungal pneumonia	4	173	Dead	–
11	Liver	IV	NR	CMV	Sepsis	4	53	Dead	–
12	None	III	NR	CMV	Pneumonia	4	28	Dead	–
13	Liver	III	CR	CMV	–	4	713	Alive	Liver (1,+42d)
14	None	III	CR	CMV	–	–	31	Dead	–
15	None	III	CR	CMV retinitis	–	4	821	Alive	–
16	Skin	III	CR	–	–	3	527	Alive	–
17	Skin and liver	IV	CR	–	–	4	693	Alive	Skin, liver (2,+144d)
18	None	III	CR	CMV	–	3	485	Alive	–
19	Skin and liver	IV	PR	–	Pneumonia	4	524	Alive	–
20	Skin and liver	IV	CR	CMV + EBV	–	4	458	Alive	–
21	None	III	CR	CMV	Intestinal infection	4	384	Alive	–

HSCT hematopoietic stem cell transplantation, aGHVD acute graft-versus-host disease, AML acute myelogenous leukemia, MDS myelodysplastic syndrome, ALL acute lymphoblastic leukemia, SAA severe aplastic anemia, HAL hybrid acute leukemia, CR complete response, NR no response, PD progressive disease, MUD matched unrelated donor, HRD haplo-identical related donor, BM bone marrow, PB peripheral blood, CSA cyclosporine A, MMF mycophenolate mofetil, MTX methotrexate, FK506 tacrolimus, ATG anti-thymocyte globulin

ISSN: 2162-3619